PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance

M Rose, JT Burgess, K O'Byrne, DJ Richard… - Frontiers in cell and …, 2020 - frontiersin.org
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …

PARP and PARG inhibitors in cancer treatment

D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

MM Gounder, NP Agaram, SE Trabucco… - Nature …, 2022 - nature.com
There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality

X Li, L Zou - The Journal of clinical investigation, 2024 - jci.org
Mutations in the tumor-suppressor genes BRCA1 and BRCA2 resulting in BRCA1/2
deficiency are frequently identified in breast, ovarian, prostate, pancreatic, and other …

Protein post-translational modifications in the regulation of cancer hallmarks

H Wang, L Yang, M Liu, J Luo - Cancer gene therapy, 2023 - nature.com
Posttranslational modifications (PTMs) of proteins, the major mechanism of protein function
regulation, play important roles in regulating a variety of cellular physiological and …

BRCAness revisited

CJ Lord, A Ashworth - Nature Reviews Cancer, 2016 - nature.com
Over the past 20 years, there has been considerable progress in our understanding of the
biological functions of the BRCA1 and BRCA2 cancer susceptibility genes. This has led to …

Ewing's sarcoma

N Riggi, ML Suvà, I Stamenkovic - New England Journal of …, 2021 - Mass Medical Soc
Ewing's Sarcoma Ewing's sarcoma, an aggressive cancer of bone and soft tissue, primarily
affects children and young adults. A t (11; 22) translocation is noted in 85 to 90% of cases …

Ewing sarcoma: current management and future approaches through collaboration

N Gaspar, DS Hawkins, U Dirksen, IJ Lewis… - Journal of Clinical …, 2015 - ascopubs.org
Ewing sarcoma (ES) is an aggressive sarcoma of bone and soft tissue occurring at any age
with a peak incidence in adolescents and young adults. The treatment of ES relies on a …

Review of various NAMPT inhibitors for the treatment of cancer

Y Wei, H **ang, W Zhang - Frontiers in Pharmacology, 2022 - frontiersin.org
Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in the NAD
salvage pathway of mammalian cells and is overexpressed in numerous types of cancers …

EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma

A Gorthi, JC Romero, E Loranc, L Cao, LA Lawrence… - Nature, 2018 - nature.com
Ewing sarcoma is an aggressive paediatric cancer of the bone and soft tissue. It results from
a chromosomal translocation, predominantly t (11; 22)(q24: q12), that fuses the N-terminal …